It was revealed last week that venerable automaker Tesla Motors Inc (NASDAQ:TSLA) (you know, the one that designed and manufactured the $59,000 – $100,000+ electric Model S) had less-than-optimal security around the iOS app that lets Model S owners unlock their cars. The problem was an easily cracked password system that allowed persistent hackers to both find and unlock the high-end cars. Tesla Motors Inc (NASDAQ:TSLA) stock opened today at $205.81 and is currently trading at $213.39. The stock showed a negative weekly performance of -0.07%.
SolarCity Corp (NASDAQ:SCTY) VP John M. Stanton sold 10,000 shares of SolarCity Corp stock on the open market in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $63.61, for a total value of $636,100.00. The transaction was disclosed in a legal filing with the SEC. SolarCity Corp (NASDAQ:SCTY) stock opened at $57.07, in current trading session and currently is at $57.93, by loosing -1.95%.The 52 week range of $18.00-$88.35. Company’s market capitalization is $5.31 billion.
GT Advanced Technologies Inc. (NASDAQ:GTAT) deal with Apple should be one of the key forces behind the company’s robust growth that is expected this year. This is a multi-million agreement with Apple being reported to have already made a prepayment of $578 million which will be reimbursed from 2015, for five years. GT Advanced Technologies Inc (NASDAQ:GTAT) stock is currently trading at $16.90 .The EPS of the stock is -0.70. Company’s market capitalization is $2.28 billion.
MannKind Corporation (NASDAQ:MNKD), a Valencia, California based biopharmaceutical company has waited for almost seven long years to get Afrezza approved. Afrezza if approved will be Mannkind’s first commercial drug to hit markets. Afrezza is a pre-meal rapid acting insulin dose for diabetics which can be inhaled. Afrezza can get peak insulin levels within 12 to 15 minutes of inhalation, as the drug delivers insulin rapidly in to bloodstream. Company is marketing a device called Dreamboat to inhale this rapid acting inhalable insulin medicine. The drug has been rejected twice by FDA, and is up for approval for the third time. FDA is expected to come out with decision by April 15, 2014. MannKind Corporation (NASDAQ:MNKD) stock opened the session at $6.12, and now is at $6.27. The 52 week range of the MNKD stock remained $3.60-$8.70 and the day range was $5.97-$6.44.
Leave a Reply